Tesamorelin Compared With Sermorelin, CJC-1295 and Ghrelin Mimetics: Structure, Duration of Action and Evidence Base

RESEARCH · TESAMORELIN · GHRH ANALOGUES & SECRETAGOGUES

Tesamorelin Compared With Sermorelin, CJC-1295 and Ghrelin Mimetics: Structure, Duration of Action and Evidence Base

PurixLab’s Tesamorelin 5mg is a research vial of a stabilised growth hormone-releasing hormone (GHRH) analogue. Our earlier articles cover the GHRH analogue overview, visceral fat and liver trials, pharmacokinetics and GH pulsatility, cognition and analytical methods. This article places tesamorelin alongside the other compounds that act on the growth hormone (GH) axis upstream of GH itself: sermorelin and CJC-1295 on the GHRH receptor, and ghrelin mimetics such as ipamorelin, ibutamoren, macimorelin and anamorelin on the ghrelin receptor. The aim is to compare structure, duration of action and, above all, the quality of the published evidence. These are findings from published research; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.

Two receptors, two families

GH release from the pituitary is driven by hypothalamic GHRH and, through a separate receptor, by the stomach peptide ghrelin. Ghrelin was later identified as the endogenous ligand of the GH secretagogue receptor (GHS-R): a 28-amino-acid peptide whose serine 3 is n-octanoylated, a modification essential for its activity [1]. Synthetic GH-releasing peptides came first, discovered in 1981, before the receptor was cloned and orally active mimetics were developed [2]. Reviews of the secretagogue class emphasise that these agents promote pulsatile GH release that remains subject to negative feedback, in contrast to exogenous GH [3].

The GHRH analogues

Tesamorelin. Tesamorelin (TH9507) is the full-length human GHRH(1-44) amide with a trans-3-hexenoyl group added to Tyr1. Non-clinical work showed that this modification made it resistant to dipeptidyl aminopeptidase-IV inactivation and slowed its degradation in rat, dog and human plasma; in dogs the apparent elimination half-life was still short, at 21 to 45 minutes [4]. Its human evidence base is the strongest of any compound here. In a randomised trial in 412 people with HIV and abdominal fat accumulation, visceral adipose tissue fell by 15.2% with tesamorelin and rose by 5.0% with placebo, and IGF-I rose by 81.0% [5]. A pooled analysis of two phase 3 trials with 806 participants and a safety extension reported no clinically meaningful changes in glucose parameters at week 26 or week 52 [6]. A review noted that stopping treatment leads to a prompt return of truncal fat and that long-term cardiovascular outcomes remain uncertain [7].

Sermorelin. Sermorelin is a 29-amino-acid analogue, the shortest synthetic peptide with the full biological activity of GHRH. Its evidence comes mainly from use as a provocative diagnostic test and from limited data in prepubertal children with idiopathic GH deficiency, where increases in height velocity were smaller than with somatropin and its effect on final adult height had not been determined [8].

CJC-1295. CJC-1295 is a GHRH analogue designed to bind albumin after administration. In two randomised, placebo-controlled trials in healthy adults aged 21-61 years, it raised mean GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9-11 days, with an estimated half-life of 5.8-8.1 days [9]. A follow-up study using overnight sampling every 20 minutes found that GH pulsatility was preserved: pulse frequency and size were unchanged, but trough GH rose 7.5-fold, mean GH 46% and IGF-I 45% [10]. These remain small, short studies; we found no published phase 3 programme in PubMed.

The ghrelin-receptor agonists

Ipamorelin. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2). In rat pituitary cells it released GH with potency and efficacy similar to GHRP-6, and in swine, unlike GHRP-6 and GHRP-2, it did not raise ACTH or cortisol beyond the levels seen with GHRH, which led its developers to call it the first selective GH secretagogue [11]. Its published record is predominantly preclinical.

Ibutamoren (MK-677). This orally active, non-peptide mimetic has the longest human trials in the class. In thirty-two healthy older adults, two weeks of treatment increased mean 24-hour GH by 97%, raised IGF-I into the young-adult range and increased fasting glucose from 5.4 to 6.8 mmol/L at 4 weeks [12]. A 2-year randomised trial in 65 adults aged 60-81 years found that fat-free mass increased by 1.1 kg compared with a 0.5 kg decrease on placebo, with no significant difference in visceral fat; fasting glucose rose by an average of 0.3 mmol/L, insulin sensitivity decreased, and the gain in fat-free mass did not change strength or function [13].

Macimorelin. Macimorelin is an oral secretagogue developed as a diagnostic agent. In a crossover trial against the insulin tolerance test, it showed sensitivity of 87% and specificity of 96% for adult GH deficiency, with 97% reproducibility on retesting; a post hoc GH cutoff of 5.1 ng/mL gave 92% sensitivity and 96% specificity [14].

Anamorelin. Anamorelin was tested in two phase 3 trials (ROMANA 1 and 2, with 484 and 495 patients) in non-small-cell lung cancer cachexia. Lean body mass increased relative to placebo in both trials, but handgrip strength, the co-primary endpoint, did not differ [15].

Comparing the evidence

  • Endpoint type. Tesamorelin’s trials measured a prespecified imaging endpoint, visceral fat by CT, in hundreds of participants [5,6]. Macimorelin was validated for diagnostic accuracy, not for any long-term outcome [14].
  • Mass versus function. In both the ibutamoren and anamorelin trials, lean or fat-free mass increased without a matching gain in strength or function [13,15].
  • Glucose. Ibutamoren raised fasting glucose and lowered insulin sensitivity [12,13], and secretagogue reviews flag blood-glucose increases as a concern [3]; the tesamorelin pooled analysis did not find clinically meaningful glucose changes [6].
  • Duration of action. Albumin binding gave CJC-1295 a half-life measured in days [9], whereas tesamorelin’s modification mainly protects it from enzymatic cleavage [4].
  • Grey-market use. A 2026 review of peptides sold as research compounds grouped GHRH analogues and secretagogues into evidence tiers ranging from regulatory-grade randomised trials to a complete absence of human studies, and listed reported problems including prolactin and cortisol elevations, appetite changes, dysglycaemia, fluid retention and uncertainty about product composition [16].

What remains open

  • No head-to-head trials compare these agents; the comparisons above are across different populations and designs [3].
  • Long-term safety, including cancer incidence and mortality, has not been established for the secretagogue class [3].
  • For tesamorelin, durable benefit after stopping treatment and effects on cardiovascular outcomes remain uncertain [7].

Tesamorelin 5mg at PurixLab

Tesamorelin 5mg: a labelled lyophilized research vial with 5mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tesamorelin-5mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View Tesamorelin 5mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-60. PubMed 10604470 · doi:10.1038/45230
  2. Thorner MO, Chapman IM, Gaylinn BD, et al. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging. Recent Prog Horm Res. 1997;52:215-44; discussion 244-6. PubMed 9238854
  3. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PubMed 28400207 · PMC5632578 · doi:10.1016/j.sxmr.2017.02.004
  4. Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58. PubMed 17214611 · doi:10.1111/j.1742-7843.2007.00008.x
  5. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. PubMed 18057338 · doi:10.1056/NEJMoa072375
  6. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304. PubMed 20554713 · doi:10.1210/jc.2010-0490
  7. Falutz J. Tesamorelin: a novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue. Drugs Today (Barc). 2011;47(6):419-30. PubMed 21695284 · doi:10.1358/dot.2011.47.6.1603439
  8. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57. PubMed 18031173 · doi:10.2165/00063030-199912020-00007
  9. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed 16352683 · doi:10.1210/jc.2005-1536
  10. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. PubMed 17018654 · doi:10.1210/jc.2006-1702
  11. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PubMed 9849822 · doi:10.1530/eje.0.1390552
  12. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-57. PubMed 8954023 · doi:10.1210/jcem.81.12.8954023
  13. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-11. PubMed 18981485 · PMC2757071 · doi:10.7326/0003-4819-149-9-200811040-00003
  14. Garcia JM, Biller BMK, Korbonits M, et al. Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab. 2018;103(8):3083-3093. PubMed 29860473 · doi:10.1210/jc.2018-00665
  15. Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17(4):519-531. PubMed 26906526 · doi:10.1016/S1470-2045(15)00558-6
  16. Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed 42395176 · PMC13322892 · doi:10.3389/fendo.2026.1822475

Leave a Comment

Your email address will not be published. Required fields are marked *